Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
European Journal of Haematology
|
June 19, 2014
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients
Lucie Oberic, Willy Vaillant, Benjamin Hebraud, et al.
Bone
|
October 11, 2017
DKK1 and sclerostin are early markers of relapse in multiple myeloma
Charlotte Mabille, Adeline Ruyssen-Witrand, Yannick Degboe, et al.
Case Reports in Hematology
|
June 8, 2026
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report
Mehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, et al.
Clinical Hematology International
|
February 13, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, et al.
Stem Cells International
|
March 28, 2020
Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
Nicolas Espagnolle, Benjamin Hebraud, Jean-Gérard Descamps, et al.
British Journal of Haematology
|
May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study
Arthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Frontiers in Physiology
|
April 4, 2017
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
Felicity Kendrick, Neil D Evans, Bertrand Arnulf, et al.
Leukemia & Lymphoma
|
February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
Frontiers in Oncology
|
November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Laura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
European Journal of Haematology
|
June 19, 2014
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients
Lucie Oberic, Willy Vaillant, Benjamin Hebraud, et al.
Bone
|
October 11, 2017
DKK1 and sclerostin are early markers of relapse in multiple myeloma
Charlotte Mabille, Adeline Ruyssen-Witrand, Yannick Degboe, et al.
Case Reports in Hematology
|
June 8, 2026
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report
Mehdi Loukhnati, Benjamin Hebraud, Marine Cazaux, et al.
Clinical Hematology International
|
February 13, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, et al.
Stem Cells International
|
March 28, 2020
Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
Nicolas Espagnolle, Benjamin Hebraud, Jean-Gérard Descamps, et al.
British Journal of Haematology
|
May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study
Arthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Frontiers in Physiology
|
April 4, 2017
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
Felicity Kendrick, Neil D Evans, Bertrand Arnulf, et al.
Leukemia & Lymphoma
|
February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
Frontiers in Oncology
|
November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Laura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Page
of 3